Abstract Background: Temozolomide is a widely used chemotherapy agent for the treatment of malignant gliomas and other brain tumors. Despite its established therapeutic benefits, there is an ongoing
*AE = Adverse Event; a = the number of reports involving the drug of interest j and adverse event of interest i combination; b = reports of adverse event of interest i observed with other drugs; c = r
his dataset supports a real-world pharmacovigilance study that evaluates and compares adverse events (AEs) associated with five biologics—efgartigimod, rozanolixizumab, eculizumab, ravulizumab, and zi
Measles, mumps, rubella, and varicella (MMRV) vaccines are widely used in global immunization programs, but safety data on their administration in children remain limited. We analyzed adverse events f
